Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT02868632
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸New York University School of Medicine, New York, New York, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT02821754
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 69
- Registration Number
- NCT02819596
- Locations
- 🇬🇧
Thomas Powles, London, United Kingdom
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
- Conditions
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT02815995
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
- Conditions
- HydronephrosisInfiltrating Bladder Urothelial Carcinoma Sarcomatoid VariantInfiltrating Bladder Urothelial Carcinoma, Micropapillary VariantInfiltrating Bladder Urothelial Carcinoma, Plasmacytoid VariantInfiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid VariantRenal Pelvis Urothelial CarcinomaStage II Bladder Urothelial Carcinoma AJCC v6 and v7Stage II Renal Pelvis Cancer AJCC v7Stage II Ureter Cancer AJCC v7Stage II Urethral Cancer AJCC v7
- Interventions
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT02812420
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 52
- Registration Number
- NCT02788773
- Locations
- 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦London Regional Cancer Program, London, Ontario, Canada
🇨🇦Odette Cancer Centre, Toronto, Ontario, Canada
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Moshe Ornstein
- Target Recruit Count
- 29
- Registration Number
- NCT02762006
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT02754856
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 73
- Registration Number
- NCT02735239
- Locations
- 🇬🇧
Research Facility, Southampton, United Kingdom
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT02718911
- Locations
- 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.